Neurogastrx Shows It Can Offset GLP-1 Side Effects

Firm Thinks Payers Will Cover An Add-On To Improve Compliance

 
• By Joseph Haas
  
Neurogastrx is looking to improve therapeutic compliance in patients taking GLP-1 agonists (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas